There is one clinical trial.
CovidSurg-Cancer is an international, multicentre, observational cohort study designed to evaluate the 30-day COVID-19 infection rates in elective cancer surgery during the COVID-19 pandemic. Centres can elect to include one or more cancer types in the study, in any combination, depending on local expertise and capacity. During the pilot study, investigators should enrol patients with confirmed diagnoses of: - Colorectal cancer - Oesophagogastric cancer As a rapid response study to the COVID-19 pandemic, included cancer types will evolve throughout the course of the CovidSurg-Cancer study period, for example, to include breast, liver, pancreatic, gynaecological, urological cancers, or sarcomas.
Description: Frequency of COVID-19 infection within 30 daysMeasure: 30-day postoperative COVID-19 infection rate Time: 30 days
Description: Number of deaths at 30-days post surgeryMeasure: 30-day postoperative mortality rate Time: 30-days
Description: Critical care utilisation in high-risk cancer surgery patientsMeasure: Postoperative critical care utilisation rate in high-risk cancer surgery patients. Time: 30-days
Description: Number of patients with a delay of more than 4 weeks from the decision taken for surgery to the date of surgeryMeasure: Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery Time: More than 4 weeks from decision date
Description: Number of non-operated patients with progression to incurable disease by 3-months after decision for surgeryMeasure: Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery Time: Up to 3-months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports